Clinical Trial ProgressProQR is viewed as a buy ahead of the 4Q 2025 AX-0810 Phase 1 readout, representing a significant event for Axiomer RNA editing.
Platform PotentialThe upcoming Phase 1 trial is designed to maximize interpretability of safety, pharmacokinetics, and biomarker data, which is crucial for understanding platform potential.
Strategic PartnershipsStrategic alignment remains strong, with Eli Lilly expanding its partnership to 15 CNS/PNS targets and reaffirming confidence through direct equity participation.